What question did this study set out to answer?

This study aims to evaluate rates of pathologic complete response (pCR) and identify predictors in node-positive breast cancer patients after neoadjuvant chemotherapy.

March 26, 2026Open Access

Pathologic Complete Response After Neoadjuvant Chemotherapy in Node-Positive Breast Cancer Patients: Regional Analysis of the Breast and Axilla

ÖAÖ AydoğanAdnan Menderes University ASAhmet Ege Sakur

Puntos clave

This study aims to evaluate rates of pathologic complete response (pCR) and identify predictors in node-positive breast cancer patients after neoadjuvant chemotherapy.
Retrospective review of 212 women with node-positive invasive breast cancer treated with neoadjuvant chemotherapy and surgery.
Analysis of breast, axillary, and overall pCR rates.
Evaluation of associations between pCR and clinical stage, tumor characteristics, and molecular subtypes.
Breast pCR rate was 32%, axillary pCR rate was 61%, and overall pCR rate was 29%.
Axillary pCR exceeded breast pCR across all molecular subtypes.

Resumen

Background and Objectives: Pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC) is a strong prognostic marker in breast cancer and may guide de-escalation of axillary surgery. This study evaluates breast, axillary, and overall pCR rates in initially node-positive patients and examines clinicopathologic predictors of response. Materials and Methods: We retrospectively reviewed 212 women with node-positive invasive breast cancer treated with NAC followed by surgery between February 2019 and July 2025. Breast pCR was defined as ypT0/Tis, axillary pCR as ypN0, and overall pCR as simultaneous clearance of invasive disease in both regions. Associations between pCR and clinical stage, tumor characteristics, and molecular subtypes were analyzed. Results: Breast, axillary, and overall pCR rates were 32%, 61%, and 29%, respectively. Axillary pCR exceeded breast pCR across all subtypes (p

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo